Yale Cancer Center shared a post on X:
“Drs. Alessandro Santin and Stefania Bellone share promising data on a ph II study (NCT06028932) of sacituzumab govitecan for ovarian cancer: 35% had tumor shrinkage and 40% had stable disease in 20 heavily pretreated patients.”
Other articles about Yale Cancer Center on OncoDaily.